Long And Winding Road To MEK Inhibition
This article was originally published in Pharmaceutical Approvals Monthly
Early MEK inhibitors failed in trials for a variety of reasons, including adverse events. GlaxoSmithKline designed its development program for trametinib, which just performed well in Phase III, with lessons learned from trials of other drugs.
You may also be interested in...
As if moving on from failures of the past, MEK inhibitors are now being positioned as part of the next standard of care in BRAF-mutant melanoma. Glaxo prepares to file trametinib as a monotherapy in 2012, after reporting striking Phase III results, while Novartis/Array’s MEK 162 demonstrates value in area of unmet need.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.